Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 01/13/21
Ekso Bionics' Stockholders Elect Mary Ann Cloyd and Rhonda A. Wallen to its Board of DirectorsGlobeNewsWire • 12/30/20
Ekso Bionics Announces Continued Adoption of EVO™ with Flexible Subscription-Based Order from Cloverdale Foods CompanyGlobeNewsWire • 11/10/20
Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/30/20
Ekso Bionics Announces EGM Builders as First Customer to Adopt EVO TechnologyGlobeNewsWire • 10/29/20
Ekso Bionics® to Report Third Quarter 2020 Financial Results on October 29, 2020GlobeNewsWire • 10/22/20
Ekso Bionics to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 16, 2020GlobeNewsWire • 09/09/20
Ekso Bionics® Unveils its Latest Assistive Exoskeleton Innovation for Industrial UseGlobeNewsWire • 08/20/20
Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/31/20
Ekso Bionics® to Report Second Quarter 2020 Financial Results on July 30, 2020GlobeNewsWire • 07/23/20
Army Distaff Foundation-Knollwood is First Life Plan Community to Adopt Ekso Bionics’ Exoskeleton Device for Rehabilitation Following Successful TrialGlobeNewsWire • 07/09/20
Ekso Bionics shares soar after company gets FDA clearance to use robotic exoskeleton in acquired brain injuryMarket Watch • 06/25/20
Ekso Bionics® Receives FDA Clearance to Market its EksoNR™ Robotic Exoskeleton for Use with Acquired Brain Injury PatientsGlobeNewsWire • 06/25/20
Ekso Bionics Announces Closing of $7.89 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 06/10/20
Ekso Bionics Announces $7.89 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 06/08/20
Ekso Bionics® Named “Best Healthcare Robotics Company” in 2020 MedTech Breakthrough Awards ProgramGlobeNewsWire • 06/03/20